Profile picture

Mr Sho Nakao

Kansai Rosai Hospital, Amagasaki (Japan)
Membership: ESC Professional Member
Follow
Logo ESC

Contributor content

Dual pathway inhibitor therapy switched from dual antiplatelet therapy reduces risk of recurrent in-stent occlusion after endovascular therapy for femoropopliteal in-stent occlusion.
Presentation
Dual pathway inhibitor therapy switched from dual antiplatelet therapy reduces risk of recurrent in-stent occlusion after endovascular therapy for femoropopliteal in-stent occlusion.
Read more

ESC 365 is supported by

novartis Explore sponsored resources